Last Price
0.003
Today's Change
+0.001 (50.00%)
Day's Change
0.002 - 0.003
Trading Volume
7,117,569
Exchange: Australian Securities Exchange Australian Securities Exchange
Currency: AUD AUD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Thian Chew Mr. Thian Chew
Full Time Employees: 8 8
IPO Date: 2010-02-14 2010-02-14
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.